Etrasimod

Drug Profile

Etrasimod

Alternative Names: APD 334

Latest Information Update: 07 Apr 2017

Price : $50

At a glance

  • Originator Arena Pharmaceuticals
  • Class Antirheumatics; Small molecules
  • Mechanism of Action Sphingosine 1 phosphate receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Inflammatory bowel diseases; Primary biliary cirrhosis; Pyoderma; Ulcerative colitis

Most Recent Events

  • 06 Apr 2017 Phase-II clinical trials in Primary biliary cirrhosis (PO) (Arena pharmaceuticals pipeline, April 2017)
  • 15 Mar 2017 Arena pharmaceuticals has patent protection for etrasimod in USA, China, Japan, Germany, France, Spain, Italy, the United Kingdom, Australia and Russia (Arena pharmaceuticals form 10-k, March 2017)
  • 15 Mar 2017 Arena pharmaceuticals has patents pending for etrasimod in Brazil, India, Canada and South Korea (Arena pharmaceuticals form 10-k, March 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top